Dr. Ruben Mesa, now Director at the UT Health San Antonio. Cancer Center, provides a 2018 update on the treatment of myeloproliferative neoplasms (myelofibrosis, polycythemia vera and essential thrombocythemia. He focuses on the MPN results from the December 2017 meeting of the American Society of Hematology. Follow Dr Mesa on twitter @mpdrc and the UT Health San Antonio Cancer Center @UTHealthCancer.
Ruben Mesa, M.D., Chair of Hematology and Oncology at Mayo Clinic in Arizona, discusses common patient questions regarding myeloproliferative neoplasms with John Camoriano, M.D., medical oncology consultant at Mayo Clinic.
Ruben Mesa, M.D. and Veena Fauble, M.D., Mayo Clinic hematologists, discuss bone marrow transplant as a treatment option for patients diagnosed with myelofibrosis.
Ruben Mesa, M.D., hematologist and Deputy Director of the Mayo Clinic Cancer Center in Arizona, provides his top ten recommendations for battling the fatigue associated with a diagnosis of myeloproliferative neoplasm.
“Living well with blood disorders”.
“Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses MPD-RC 112, a randomized trial of pegylated interferon alfa-2a versus hydroxyurea therapy in the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET).”
What tests are important for an MPN patient as they go on their journey? MPN Expert, Dr. Srdan Verstovsek, explains.
Advances in treatment for MDS/MPN are not keeping pace with the rapid improvement in understanding of the genetics of these diseases. Too little is known about how to treat these patients.
Diagnosis of MDS or MDS/MPN must begin with morphology (analysis of the form and structure of patient blood or bone marrow cells). When used alone, today’s advanced techniques to study genes and chromosomes don’t give enough information to find out what type of MDS or MDS/MPN a patient has.